Carmignac Gestion’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Carmignac Gestion’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-27,804	Closed	-$1.63M	–	167
2023 Q4	$1.63M	Buy	+27,804	New	+$1.56M	0.03%	114

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Carmignac Gestion's MRTX Position: Q1 2024 in Review

Carmignac Gestion sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 27,804 shares — an estimated $1.63M sold.

Carmignac Gestion first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $1.63M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Carmignac Gestion reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Carmignac Gestion sold 27,804 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.63M.
Carmignac Gestion first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Carmignac Gestion's Mirati Therapeutics, Inc. Common Stock position peaked at $1.63M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Carmignac Gestion's 13F filing for Q1 2024, filed 14 May 2024.